NasoClenz has potential to increase CPAP compliance, study finds 

FRISCO, Texas – NasoClenz reduced bacterial colonization, while increasing comfort and compliance, in patients who use CPAP therapy to treat sleep apnea, according to the results of a clinical evaluation recently presented at the American College of Surgeons Clinical Congress. “Sleep apnea is a very serious health issue,” said lead author and presenter Keith Matheny, MD, FARS. “Anything we can offer patients that might help improve compliance with CPAP will have a tremendous impact on patients’ lives.” This initial evaluation included a group of routine CPAP patients who were given NasoClenz, an antiseptic cleansing kit that includes anatomically designed, soft nasal applicators used in conjunction with a specially formulated antiseptic gel. Participants used the pre-packaged NasoClenz kits before and after using CPAP for a period of two weeks. They completed a survey before the study started and after two weeks. In the “after” survey, more than 50% of participants reported that the kits made CPAP more comfortable and at least 50% noted that this helped to increase their use of CPAP.  The results also showed a decrease in bacterial colonization. Out of 18 participants, six were randomly selected for pre- and post-study bacterial cultures. Prior to the study, 50% of those patients had antibiotic-resistant strains of bacterial colonization; following two weeks of twice-daily NasoClenz use, bacterial colonization was reduced or eliminated in all but one participant. These results were presented at the American College of Surgeons Clinical Congress Oct. 16-20 in San Diego.